Alpha Tau Medical Ltd. (DRTS) is a Jerusalem-based, clinical-stage oncology company developing Alpha DaRT, a diffusing alpha-emitters radiation therapy platform that places radium-224 sources directly inside solid tumors to destroy cancer tissue while sparing surrounding healthy cells. The company has no meaningful product revenue and is valued at roughly $1.0 billion.
In Thursday trading, the stock changed hands at $11.16, down $0.85, or 7.08%, from the previous session's close of $12.01. The decline extends a turbulent stretch: the shares peaked at $15.79 in September and have now surrendered roughly 29% from that high, including a 10.54% single-session drop on November 16 despite ostensibly positive clinical news.
No verified news or fundamental catalyst found for Thursday's decline. No new regulatory filing, partnership announcement, financing, or analyst rating change was identified around the time of the move, and the company did not disclose any new clinical or financial information that would account for a 7% slide.
The most plausible explanation is a continuation of the reversal that began on November 16, when Alpha Tau opened at $14.40 and closed at $11.97 after releasing updated interim REGAIN trial data in recurrent glioblastoma. Those results showed all eight treated patients alive, median overall survival not yet reached, and objective responses in all six evaluable patients — yet the stock fell sharply, a pattern consistent with profit-taking after a rally that had already priced in substantial optimism. Monday's intraday high of $14.41 marked a rejection near the prior range top, and sellers have controlled the tape since.
Two additional factors are plausibly contributing. First, the stock is trading ahead of its third-quarter financial report, which market calendars place either on November 19 before the open or later in the month; uncertainty around cash burn and trial timelines tends to invite de-risking. Second, valuations for pre-revenue oncology names have grown stretched after a 140% year-to-date gain, leaving little cushion for disappointment.
Technically, the picture is consistent with a breakdown. The shares are now below their 30-day average near $13.5 and their 100-day average near $13.6, having lost the $11.81 low set on November 16. The 200-day average around $10.9 is the next notable reference point.
Volume has been elevated over the past week but not during Thursday's early trade. Monday's session saw roughly 2.29 million shares change hands, more than four times the average of about 540,000, as the clinical update drove an unusually wide $11.81–$14.41 range. Thursday's turnover was running lighter, suggesting the decline reflects a thinner order book rather than a broad institutional exit. No sector-wide development was identified that would explain a move of this magnitude, and the selling appears company-specific rather than part of an industry rotation.
The stock's own volatility profile matters here: it has averaged an absolute daily move of about 2.5% over the past 79 sessions, including a 9.73% advance on August 4 and multiple 5%–6% swings. Sharp moves are normal for this name, which magnifies the impact of modest order-flow imbalances.
The score runs from 0, meaning no meaningful news and a move typical for the stock, to 100, meaning transformative news and an extreme, rare price move. Alpha Tau Medical earns an 18 out of 100.
Verified news strength was weak for this session: the clinical, analyst, and corporate developments that matter for the company were published earlier in the week, and Thursday brought no new disclosure. The price move, however, was unusual — 7.08% is roughly 2.8 times the stock's typical daily move, and only one session in the past 60 produced a larger swing. A meaningful but not extreme anomaly combined with an absence of fresh fundamental information produces the low score.
The immediate focus is the third-quarter report, where investors will look at cash and short-term deposits against first-half research spending and at management's commentary on trial timelines. Analysts currently hold a consensus Buy rating with a mean twelve-month target near $20, while the most recent actions include a Piper Sandler upgrade to Overweight with a $22 target in mid-November.
Operationally, watch for updated REGAIN enrollment, top-line ReSTART skin cancer data with Breakthrough Device Designation, initial IMPACT pancreatic readouts, and progress under the Tolmar prostate collaboration. Any timeline slip, acceleration in cash burn, or adverse event would weigh on sentiment; on-schedule execution would support the bull case. Because the company remains pre-revenue, headline risk is high and quarterly losses can be distorted by non-cash warrant remeasurement.
Tickeron's Trending AI Robots page curates the automated strategies performing strongest under current market conditions. The platform hosts hundreds of AI trading bots spanning thousands of tickers, with each bot differing by strategy logic, timeframe, performance metrics, and the symbols it trades. Rather than listing everything, the Trending section surfaces only the top performers, giving traders a focused shortlist during volatile sessions like this one. Review the live leaderboard to see which strategies are adapting best to today's conditions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Oscillator for DRTS moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 20 of the 23 cases the stock moved higher. This puts the odds of a move higher at 87%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +6.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where DRTS advanced for three days, in 186 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
DRTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 151 of 179 cases where DRTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DRTS as a result. In 76 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for DRTS turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 39 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DRTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. DRTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (28.800) is normal, around the industry mean (3.592). P/E Ratio (-13.192) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DRTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology